Diabetic kidney disease (DKD) can be burdensome for patients—especially if it progresses. How can we find out if our patients are at risk of progression? To answer that question, Dr. Charles Turck is joined by Dr. Michael Donovan to discuss a prognostic tool for type 2 diabetes patients with early-stage (stage 1-3b) chronic kidney disease.

As advancements in imaging continue to emerge, what does that mean for the management of gout, calcium pyrophosphate deposition, and crystalline arthritis? To answer this question, Dr. Jason Liebowitz is joined by Dr. Sara Tedsechi from Harvard Medical School.

Dr. Liebowitz and Dr. Tedeschi are Novartis consultants.

10/22

For an asthma patient with active airway hyperresponsiveness, what kind of role do airway structural changes and mast cells play? And why is airway hyperresponsiveness so important? Professor Chris Brightling and Professor Bruce Levy share their clinical perspectives on airway hyperresponsiveness.

©2023 Amgen and AstraZeneca. All rights reserved. US-73467 Last Updated 3/23

The rate of chronic kidney disease (CKD) in patients with type 2 diabetes (T2D) continues to rise. What can we do to slow this progression of CKD? Dr. Joseph Aloi from the Wake Forest School of Medicine explores this growing epidemic and discusses how a new tool may aid in early risk assessment of early stage 1-3b CKD.

So how and when should we escalate or change treatments in patients with psoriatic arthritis (PsA)? To answer this question, Dr. Ethan Craig is joined by Dr. Alexis Ogdie-Beatty from the Perelman School of Medicine at the University of Pennsylvania.

Dr. Craig and Dr. Ogdie-Beatty are Novartis consultants.

221663 7/22

How should gout be classified? To help us better understand the epidemiology and pathogenesis of gout, Dr. Jason Liebowitz is joined by Dr. Sara Tedeschi from Harvard Medical School.

Dr. Liebowitz and Dr. Tedeschi are Novartis consultants.

10/22 236268

Even though biosimilars serve as a much-needed treatment option for patients in several fields of medicine, gastroenterologists have been reluctant to adopt them. Joining Dr. Jennifer Caudle to explore why this might be and the evolving role of biosimilars in anti-inflammatory care for GI patients is Dr. Stephen Hanauer, Professor of Medicine at the Northwestern University Feinberg School of Medicine in Chicago, Illinois.

USA-CBU-81030

Prior to 2008, there were limited approved treatment options for hereditary angioedema (HAE) available in the United States, but today, there are several medications approved by the U.S. Food and Drug Administration for preventing and treating HAE attacks.1 In light of the number of therapies that have been approved in recent years and continued clinical advancements in HAE research, what do we need to consider when discussing these treatment options with our patients? Here to share those key considerations and important information on the HAE treatment landscape is Dr. Marc Riedl.

References:

1. Busse PJ, Christiansen SC, Riedl MA, Banerji A, Bernstein JA, Castaldo AJ, Craig T, Davis-Lorton M, Frank MM, Li HH, Lumry WR, Zuraw BL. US HAEA Medical Advisory Board 2020 Guidelines for the Management of Hereditary Angioedema. J Allergy Clin Immunol Pract. 2021 Jan;9(1):132-150.e3.

©2022 Takeda Pharmaceutical Company Limited. All rights reserved.
US-NON-7747v1.0 09/22

What are some way we can overcome the challenges that come with monitoring response to therapy for patients with psoriatic arthritis (PsA)? Dr. Ethan Craig is joined by Dr. Alexis Ogdie-Beatty from the Perelman School of Medicine at the University of Pennsylvania to discuss the importance of monitoring and share strategies.

Dr. Craig and Dr. Ogdie-Beatty are Novartis consultants.

221663 7/22

What do we need to know about the epidemiology and pathogenesis of calcium pyrophosphate deposition? Dr. Jason Liebowitz is joined by Dr. Sara Tedeschi from Harvard Medical School to share key insights on CPPD.

Dr. Liebowitz and Dr. Tedeschi are Novartis consultants

10/22 236268